Fluticasone Propionate And Salmeterol Powder
Product Images NDC 70518-4346

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Fluticasone Propionate And Salmeterol (NDC 70518-4346). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Remedy_label (Remedy Label)

This is a description of Fluticasone Propionate/Salmeterol inhalation powder with a strength of 100mcg/50mcg in 60 blister packs. It is intended for oral inhalation only and should be stored in a dry place away from direct heat or sunlight. The medication was repackaged by RemedyRepack Inc. in Indiana and the original manufacturer is Prasco Laboratories in Mason, Ohio. Keep the medication out of the reach of children and store it at 20-25°C (68-77°F) with excursions permitted to 15-30°C (59-86°F).*

FDA Label Image

Fluticasone Propionate Chemical Structure (Fp Sal Spl Graphic 01)

FDA Label Image

Salmeterol Xinafoate Chemical Structure (Fp Sal Spl Graphic 02)

FDA Label Image

Figure 1. Mean Percent Change From Baseline In Fev1 In Subjects With Asthma Previously Treated With Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 03)

This text shows data related to a study comparing the impact on FEV (Forced Expiratory Volume) of different medication regimens. Fluticasone propionate/salmeterol combination, fluticasone propionate alone, salmeterol alone, and placebo were administered to the subjects. The text also includes percentage changes in FEV over time.*

FDA Label Image

Figure 2. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 04)

This information shows the percentage change in FEV4 for different treatments over time. The data includes treatments with Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The measurements are taken on Day 1 and at Baseline for comparison.*

FDA Label Image

Figure 3. Percent Change In Serial 12-hour Fev1 In Subjects With Asthma Previously Using Either Inhaled Corticosteroids Or Salmeterol (trial 1) (Fp Sal Spl Graphic 05)

This is an evaluation chart showing the % Change in Forced Expiratory Volume (FEV) relative to the Day 1 Baseline for different treatment groups. The treatments include Fluticasone propionate/salmeterol 100/50 mcg twice daily, Salmeterol 50 mcg twice daily, Fluticasone propionate 100 mcg twice daily, and Placebo. The chart displays data for different time points from Day 1 to Week 12.*

FDA Label Image

Figure 4. Predose Fev1: Mean Percent Change From Baseline In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 06)

This is a table showing results of a study with Fluticasone propionate/salmeterol DISKUS 250/50 mcg twice daily compared to Salmeterol 50 mcg twice daily and Placebo. The study measured FEV1 values over weeks, showing the effectiveness of the medications.*

FDA Label Image

Figure 5. Two-hour Postdose Fev1: Mean Percent Changes From Baseline Over Time In Subjects With Chronic Obstructive Pulmonary Disease (Fp Sal Spl Graphic 07)

This text provides data on the comparison of the effects of Fluticasone propionate/salmeterol, Fluticasone propionate, and Placebo on baseline FEV. The study includes measurements at different time points and shows the number of participants for each group.*

FDA Label Image

Figure A (Fp Sal Spl Graphic 08)

This text provides details about a medication called "Putiasone" paired with "Salmeterol DISKUS" for inhalation through a powder dosage form. The text mentions a "Mouthpiece" and "Lever" possibly related to the administration of the medication.*

FDA Label Image

Figure B (Fp Sal Spl Graphic 09)

FDA Label Image

Figure C (Fp Sal Spl Graphic 10)

FDA Label Image

Figure D (Fp Sal Spl Graphic 11)

FDA Label Image

Figure E (Fp Sal Spl Graphic 12)

FDA Label Image

Figure F (Fp Sal Spl Graphic 13)

FDA Label Image

Figure G (Fp Sal Spl Graphic 14)

FDA Label Image

Figure H (Fp Sal Spl Graphic 15)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.